TGF-.beta. antagonists as mitigators of radiation-induced tissue damage
Abstract
A method for treating tissue damage caused by radiation is described by use of a TGF-.beta. antagonist, such as an anti-TGF-.beta. antibody or a TGF-.beta. latency associated protein. It is administered not more than a week after exposure, and is particularly useful in mitigating the side effects of breast cancer therapy.
- Inventors:
-
- Oakland, CA
- Issue Date:
- Research Org.:
- Lawrence Berkeley National Lab. (LBNL), Berkeley, CA (United States)
- OSTI Identifier:
- 870891
- Patent Number(s):
- 5616561
- Assignee:
- Regents of University of California (Oakland, CA)
- Patent Classifications (CPCs):
-
A - HUMAN NECESSITIES A61 - MEDICAL OR VETERINARY SCIENCE A61K - PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
C - CHEMISTRY C07 - ORGANIC CHEMISTRY C07K - PEPTIDES
- DOE Contract Number:
- AC03-76SF00098
- Resource Type:
- Patent
- Country of Publication:
- United States
- Language:
- English
- Subject:
- tgf-; beta; antagonists; mitigators; radiation-induced; tissue; damage; method; treating; caused; radiation; described; antagonist; anti-tgf-; antibody; latency; associated; protein; administered; week; exposure; particularly; useful; mitigating; effects; breast; cancer; therapy; tissue damage; breast cancer; particularly useful; cancer therapy; damage caused; /514/
Citation Formats
Barcellos-Hoff, Mary H. TGF-.beta. antagonists as mitigators of radiation-induced tissue damage. United States: N. p., 1997.
Web.
Barcellos-Hoff, Mary H. TGF-.beta. antagonists as mitigators of radiation-induced tissue damage. United States.
Barcellos-Hoff, Mary H. Wed .
"TGF-.beta. antagonists as mitigators of radiation-induced tissue damage". United States. https://www.osti.gov/servlets/purl/870891.
@article{osti_870891,
title = {TGF-.beta. antagonists as mitigators of radiation-induced tissue damage},
author = {Barcellos-Hoff, Mary H},
abstractNote = {A method for treating tissue damage caused by radiation is described by use of a TGF-.beta. antagonist, such as an anti-TGF-.beta. antibody or a TGF-.beta. latency associated protein. It is administered not more than a week after exposure, and is particularly useful in mitigating the side effects of breast cancer therapy.},
doi = {},
journal = {},
number = ,
volume = ,
place = {United States},
year = {1997},
month = {1}
}